Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: Kinetic and X-ray crystallographic studies

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 17, 2007, Pages 4866-4872

  Temperini, Claudia ^a   Innocenti, Alessio ^a   Mastrolorenzo, Antonio ^a   Scozzafava, Andrea ^a   Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antiepileptic; Carbonic anhydrase; Sulfamate; Sulfonamide; Sultam; Sulthiame; X ray crystallography

Indexed keywords

ACETAZOLAMIDE; AMINO ACID; ANTICONVULSIVE AGENT; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DICLOFENAMIDE; DORZOLAMIDE; ETHOXZOLAMIDE; METHAZOLAMIDE; SULFONAMIDE; SULTIAME; TOPIRAMATE;

ARTICLE; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; EPILEPSY; FOCAL EPILEPSY; HUMAN; KINETICS; NONHUMAN; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTICONVULSANTS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ELECTRONS; INHIBITORY CONCENTRATION 50; KINETICS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PROTEIN ISOFORMS; THIAZINES;

MAMMALIA;

EID: 34547585390     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.06.044     Document Type: Article

References (48)

1. Huppke P., Kohler K., Brockmann K., Stettner G.M., and Gartner J.Eur. J. Ped. Neurol. 11 (2007) 10
2. Wirrell E., Ho A.W., and Hamiwka L. Ped. Neurol. 35 (2006) 204
3. Koepp M.J., Patsalos P.N., and Sander J.W. Epilepsy Res. 50 (2002) 277
4. Leninger T., Wiemann M., Bingmann D., Widman G., Hufnagel A., and Bonnet U. Epilepsia 43 (2002) 469
5. Debus O.M., and Kurlemann G. Epilepsia 45 (2004) 103
6. Engler F., Maeder-Ingvar M., Roulet E., and Deonna T. Neuropediatrics 34 (2003) 105
7. Bast T., Volp A., Wolf C., and Rating D. Epilepsia 44 (2004) 215
8. Tanimukai H., Nishimura T., and Sano I. Klin. Wochenschr. 42 (1964) 918
9. May T.W., Korn-Merker E., Rambeck B., and Boenigk H.E. Ther. Drug Monitor 16 (1994) 251
10. Thiry A., Dogne J.M., Supuran C.T., and Masereel B. Curr. Top. Med. Chem. 7 (2007) 855
11. Supuran C.T., Scozzafava A., and Casini A. Med. Res. Rev. 23 (2003) 146
12. Scozzafava A., Mastrolorenzo A., and Supuran C.T. Expert Opin. Ther. Pat. 16 (2006) 1627
13. Supuran C.T. Therapy 4 (2007) 355
14. Supuran C.T. Curr. Top. Med. Chem. 7 (2007) 825
15. Supuran C.T., and Scozzafava A. Bioorg. Med. Chem. 15 (2007) 4336
16. Pastorekova S., Parkkila S., Pastorek J., and Supuran C.T. J. Enz. Inhib. Med. Chem. 19 (2004) 199
17. Reiss W.G., and Oles K.S. Ann. Pharmacother. 30 (1996) 514
18. Casini A., Antel J., Abbate F., Scozzafava A., David S., Waldeck H., Schäfer S., and Supuran C.T. Bioorg. Med. Chem. Lett. 13 (2003) 841
19. De Simone G., Di Fiore A., Menchise V., Pedone C., Antel J., Casini A., Scozzafava A., Wurl M., and Supuran C.T. Bioorg. Med. Chem. Lett. 15 (2005) 2315
20. Parkkila S., Parkkila A.K., Rajaniemi H., Shah G.N., Grubb J.H., Waheed A., and Sly W.S. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 1918
21. Taniuchi K., Nishimori I., Takeuchi T., Ohtsuki Y., and Onishi S. Mol. Brain Res. 109 (2002) 207
22. Ghandour M.S., Parkkila A.K., Parkkila S., Waheed A., and Sly W.S. J. Neurochem. 75 (2000) 2212
23. Nishimori I. Acatalytic CAs: carbonic anhydrase-related proteins. In: Supuran C.T., Scozzafava A., and Conway J. (Eds). Carbonic anhydrase: Its inhibitors and Activators (2004), CRC Press, Boca Raton 25
24. Ruusuvuori E., Li H., Huttu K., Palva J.M., Smirnov S., Rivera C., Kaila K., and Voipio J. J. Neurosci. 24 (2004) 2699
25. Rivera C., Voipio J., and Kaila K. J. Physiol. 562 (2005) 27
26. Nishimori I., Vullo D., Innocenti A., Scozzafava A., Mastrolorenzo A., and Supuran C.T. J. Med. Chem. 48 (2005) 7860
27. Vullo D., Franchi M., Gallori E., Pastorek J., Scozzafava A., Pastorekova S., and Supuran C.T. Bioorg. Med. Chem. Lett. 13 (2003) 1005
28. Winum J.Y., Dogne J.M., Casini A., de Leval X., Montero J.L., Scozzafava A., Vullo D., Innocenti A., and Supuran C.T. J. Med. Chem. 48 (2005) 2121
29. Vullo D., Innocenti A., Nishimori I., Pastorek J., Scozzafava A., Pastorekova S., and Supuran C.T. Bioorg. Med. Chem. Lett. 15 (2005) 963
30. Nishimori I., Vullo D., Innocenti A., Scozzafava A., Mastrolorenzo A., and Supuran C.T. Bioorg. Med. Chem. Lett. 15 (2005) 3828
31. Nishimori I., Minakuchi T., Onishi S., Vullo D., Scozzafava A., and Supuran C.T. J. Med. Chem. 50 (2007) 381
32. Vullo D., Voipio J., Innocenti A., Rivera C., Ranki H., Scozzafava A., Kaila K., and Supuran C.T. Bioorg. Med. Chem. Lett. 15 (2005) 971
33. Cecchi A., Hulikova A., Pastorek J., Pastorekova S., Scozzafava A., Winum J.-Y., Montero J.-L., and Supuran C.T. J. Med. Chem. 48 (2005) 4834
34. Thiry A., Dogné J.M., Masereel B., and Supuran C.T. Trends Pharmacol. Sci. 27 (2006) 566
35. Lehtonen J., Shen B., Vihinen M., Casini A., Scozzafava A., Supuran C.T., Parkkila A.K., Saarnio J., Kivela A.J., Waheed A., Sly W.S., and Parkkila S. J. Biol. Chem. 279 (2004) 2719
36. Recacha R., Costanzo M.J., Maryanoff B.E., and Chattopadhyay D. Biochem. J. 361 (2002) 437
37. Alterio, V.; De Simone, G.; Monti, S.M.; Scozzafava, A.; Supuran, C.T. Bioorg. Med. Chem. Lett. 2007, 17, in press. (doi 10.1016/j.bmcl.2007.05.045).
38. 2 solutions in water at 20 °C were used as substrate. Stock solutions of inhibitors were prepared at a concentration of 10 mM (in DMSO-water 1:1, v/v) and dilutions up to 0.1 nM done with the assay buffer mentioned above. Inhibitor and enzyme solutions were preincubated together for 10 min at room temperature prior to assay, in order to allow for the formation of the E-I complex.
39. 23 Coordinates and structure factors have been deposited with the Protein Data Bank (PDB accession code 2Q1Q). The crystallographic parameters and refinement statistics are summarized in Table 2.
40. Winum J.Y., Temperini C., El Cheikh K., Innocenti A., Vullo D., Ciattini S., Montero J.L., Scozzafava A., and Supuran C.T. J. Med. Chem. 49 (2006) 7024
41. Oxford Diffraction. CrysAlis RED. 2006, Version 1.171.32.2. Oxford Diffraction Ltd.
42. Jones T.A., Zhou J.Y., Cowan S.W., and Kjeldoard M. Acta Crystr. A47 (1991) 110
43. Emsley P., and Cowtan K. Acta Cryst. D60 (2004) 2126
44. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. J. Appl. Crystal. 26 (1993) 283
45. Boriack P.A., Christianson D.W., Kingery-Wood J., and Whitesides G.M. J. Med. Chem. 38 (1995) 2286
46. Kim C.Y., Chang J.S., Doyon J.B., Baird T.T., Fierke C.A., Jain A., and Christianson D.W. J. Am. Chem. Soc. 122 (2000) 12125
47. Antel J., Weber A., Sotriffer C.A., and Klebe G. Multiple binding modes observed in X-ray structures of carbonic anhydrase inhibitor complexes and other systems: consequences for structure-based drug design. In: Supuran C.T., Scozzafava A., and Conway J. (Eds). Carbonic anhydrase-Its inhibitors and activators (2004), CRC Press, Boca Raton 45
48. Supuran C.T., Scozzafava A., and Casini A. Development of sulfonamide carbonic anhydrase inhibitors. In: Supuran C.T., Scozzafava A., and Conway J. (Eds). Carbonic anhydrase-Its inhibitors and activators (2004), CRC Press, Boca Raton 67